Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis.
The current study was undertaken to investigate the effect of alendronate on bone mineral density (BMD), bone metabolism markers, and serum bone-resorbing cytokines in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. Sixteen randomly selected women, 7 with CIN-associated osteoporosis and 9 with CIN-associated osteopenia, and 14 age- and menopausal status-matched healthy volunteers, were enrolled in the study. Patients received 10 mg alendronate daily per os for 360 days and studies were done before treatment (day 0) and at varying time points during the study. We found that patients' BMD measurements increased by 5.32% after treatment, and that the elevated serum osteocalcin (OC), a bone formation marker, decreased by day 30, normalized by day 90, and increased again by day 270 of treatment. Elevated values of patients' urine deoxypyridinoline (Dpd) and N-telopeptide of type I of collagen (NTx), two bone resorption markers, returned to the control range by day 30 and decreased thereafter. Increased levels of patients' serum tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta (IL-1beta), two bone resorbing cytokines, returned to the control range by day 30 and decreased thereafter. Peripheral blood neutrophil counts increased by day 30 and continued to rise thereafter, reaching a mean value higher than 2650 neutrophils per microl of blood on day 360. Interestingly, alendronate-induced changes in the levels of both cytokines correlated inversely with the respective changes in neutrophil counts and BMD measurements, and positively with the changes in the respective means of urine NTx and Dpd values. All these findings indicate that alendronate is effective in treating CIN-associated osteopenia/osteoporosis, and that the beneficial effect of the compound may lie, at least in part, in its property to inhibit the production of TNFalpha and IL-1beta by cells of the monocyte/macrophage system, in which osteoclasts are included.
Papadaki
Helen A
HA
Department of Hematology University of Crete School of Medicine, University Hospital of Heraklion, P.O. Box 1352, Heraklion, Crete, Greece.
Tsatsanis
Christos
C
Christoforidou
Anna
A
Malliaraki
Niki
N
Psyllaki
Maria
M
Pontikoglou
Charis
C
Miliaki
Maria
M
Margioris
Andrew N
AN
Eliopoulos
George D
GD
D000328:Adult; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D002908:Chronic Disease; D005260:Female; D005272:Femur Neck / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007375:Interleukin-1 / Q000097:blood*; D007958:Leukocyte Count; D008875:Middle Aged; D009503:Neutropenia / Q000097:blood* / Q000150:complications / Q000473:pathology / Q000652:urine; D009504:Neutrophils / Q000378:metabolism* / Q000473:pathology; D010024:Osteoporosis / Q000097:blood* / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
D015415:Biomarkers; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D019386:Alendronate